The macroeconomic burden of noncommunicable diseases in the United States: Estimates and projections
- PMID: 30383802
- PMCID: PMC6211719
- DOI: 10.1371/journal.pone.0206702
The macroeconomic burden of noncommunicable diseases in the United States: Estimates and projections
Abstract
We develop and calibrate a dynamic production function model to assess how noncommunicable diseases (NCDs) will affect U.S. productive capacity in 2015-2050. In this framework, aggregate output is produced according to a human capital-augmented production function that accounts for the effects of projected disease prevalence. NCDs influence the economy through the following pathways: 1) when working-age individuals die of a disease, aggregate output undergoes a direct loss because physical capital can only partially substitute for the loss of human capital in the production process. 2) If working-age individuals suffer from a disease but do not die from it, then, depending on the condition's severity, they tend to be less productive, might work less, or might retire earlier. 3) Current NCD interventions such as medical treatments and prevention require substantial resources. Part of these resources could otherwise be used for productive investments in infrastructure, education, or research and development. This implies a loss of savings across the population and hampers economy-wide physical capital accumulation. Our results indicate a total loss of USD94.9 trillion (in constant 2010 USD) due to all NCDs. Mental health conditions and cardiovascular diseases impose the highest burdens, followed by cancer, diabetes, and chronic respiratory diseases. In per capita terms, the economic burden of all NCDs in 2015-2050 is USD265,000. The total NCD burden roughly corresponds to an annual tax rate of 10.8% on aggregate income.
Conflict of interest statement
This research was also made possible by a grant from the Carnegie Corporation of New York (https://www.carnegie.org). Carnegie Corporation of New York is the philanthropic foundation established by Andrew Carnegie in 1911. We declare that this does not alter our adherence to PLOS ONE policies on sharing data and materials. The statements made and views expressed are solely the responsibility of the authors. The funder had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors have no role relating to employment, consultancy, patents, products in development, or marketed products for Carnegie Corporation of New York.
Figures
References
-
- Institute for Health Metrics and Evaluation. Global burden of disease study 2016 (GBD 2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation, 2016.
-
- Bloom DE, Chen S, Kuhn M, McGovern ME, Oxley L, Prettner K. The economic burden of chronic diseases: estimates and projections for China, Japan, and South Korea. National Bureau of Economic Research Working Paper Series, 1050 Massachusetts Avenue, Cambridge, MA 02138. 2017; No. 23601. 10.3386/w23601.
-
- Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom L, Fathima S, et al. The global economic burden of noncommunicable diseases. Geneva, Switzerland: World Economic Forum, 2011.
-
- Dwyer DS, Mitchell OS. Health problems as determinants of retirement: are self-rated measures endogenous? J Health Econ. 1999;18(2):173–93. - PubMed
-
- Lindeboom M, Kerkhofs M. Health and work of the elderly: subjective health measures, reporting errors and endogeneity in the relationship between health and work. J Appl Econometrics. 2009;24(6):1024–46.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources